Press release
Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight
Hypertrophic Cardiomyopathy Treatment Market
(Albany, UJSA) DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology and Market Forecast 2034" report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Hypertrophic Cardiomyopathy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hypertrophic Cardiomyopathy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
Unlock detailed insights into the Hypertrophic Cardiomyopathy Market by downloading the comprehensive report from DelveInsight @ Hypertrophic Cardiomyopathy Treatment Market Size [https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Hypertrophic Cardiomyopathy Market Report
* The Hypertrophic Cardiomyopathy market size was valued ~USD 646 million in 2023 and is anticipated to grow with a significant CAGR of 20% during the study period (2020-2034)
* In December 2024, Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease, has announced promising early results from the first cohort of patients in the MyPEAK-1 clinical trial of TN-201 gene therapy. TN-201 is being developed as a potential treatment for MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by inadequate levels of myosin-binding protein C (MyBP-C).
* In September 2024, Edgewise Therapeutics reported promising top-line results from two clinical trials evaluating EDG-7500 as a potential treatment for obstructive hypertrophic cardiomyopathy (HCM). The findings include data from a Phase I trial in healthy participants and the single-dose arm of the Phase II CIRRUS-HCM trial. EDG-7500, an oral and selective modulator, is specifically designed to target cardiac relaxation challenges associated with HCM.
* In April 2024, Imbria Pharmaceuticals, Inc., a clinical-stage cardiometabolic company focused on developing innovative therapies to enhance patient symptoms and functional capacity by improving cellular energetics, announced that findings from the Phase 2 IMPROVE-HCM clinical trial investigating ninerafaxstat in patients with symptomatic nHCM were unveiled during a late-breaking clinical trial session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).
* As per DelveInsight's assessments, males are more affected by HCM than females. Also, the cases are projected to increase by 2034 in the United States.
* As per assessments by DelveInsight analysts, there were nearly 2,887 diagnosed prevalent cases of Obstructive HCM (HOCM), and 1,443 diagnosed prevalent cases of Non-obstructive HCM (HNCM) in 2023 in Japan.
* In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of HCM in the 7MM was 246,272 in 2023. The highest diagnosed prevalent cases of HCM were accounted by the US for 48% in 2022 which were approximately of the 7MM. These cases are expected to increase during the forecast period (2023-2034).
* Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
* Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
Gain a competitive edge in the Hypertrophic Cardiomyopathy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Hypertrophic Cardiomyopathy Treatment Drugs [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypertrophic Cardiomyopathy Epidemiology Segmentation in the 7MM
* Total Prevalent Cases
* Diagnosed Prevalent Cases
* Gender-specific Diagnosed Prevalent Cases
* Type-specific Diagnosed Prevalent Cases
* Total Treated Cases
Hypertrophic Cardiomyopathy Market Insights
Current pharmacological strategies for hypertrophic cardiomyopathy (HCM) focus on symptom management, particularly for obstructive HCM. Treatment primarily targets left ventricular outflow tract (LVOT) obstruction, using -adrenergic antagonists, calcium channel blockers, and antiarrhythmic drugs. "CAMZYOS (Mavacamten) is the first and only cardiac myosin inhibitor approved by the US FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms."
Discover key developments and opportunities in the Hypertrophic Cardiomyopathy Market. Click here to learn more from DelveInsight's latest report @ Hypertrophic Cardiomyopathy Market Size [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypertrophic Cardiomyopathy Marketed Drugs
* Mavacamten: Bristol Myers Squibb
Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance.
Hypertrophic Cardiomyopathy Emerging Drugs
* Aficamten (CK-274): Cytokinetics
Aficamten, or CK-274, is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations for the potential treatment of hypertrophic cardiomyopathies (hypertrophic cardiomyopathy).
* MYK-224: Bristol Myers Squibb
MYK-224 is a small molecule drug that is being developed by MyoKardia, a subsidiary of Bristol-Myers Squibb, to treat diastolic heart failure (HFpEF) and obstructive hypertrophic cardiomyopathy. It is taken orally and targets the heart's cardiac myosin motor protein to normalize filling and contractility.
Hypertrophic Cardiomyopathy Market Outlook
Cardiomyopathy is a term that refers to abnormalities of heart muscle contractility, covering a heterogeneous range of etiologies. Hypertrophic cardiomyopathy is characterized by left ventricular hypertrophy and hypercontractility. It is almost always caused by mutations of genes encoding sarcomeric proteins. Current pharmacological treatment strategies of Hypertrophic cardiomyopathy are mainly centered on managing the symptoms and minimizing disease progression. However, it is important to keep in mind that these strategies are not disease-specific since they target the neurohormonal system and excitation-contraction coupling (ECC) while the basic disease mechanism remains untreated.
Download DelveInsight's Hypertrophic Cardiomyopathy Market report today and stay ahead in this rapidly evolving field. @ Hypertrophic Cardiomyopathy Clinical Trials and advancements [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Hypertrophic Cardiomyopathy Market Report
* Coverage- 7MM
* Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
* Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
* Hypertrophic Cardiomyopathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Hypertrophic Cardiomyopathy Unmet Needs, KOL's views, Analyst's views, Hypertrophic Cardiomyopathy Market Access and Reimbursement
Download the report to understand which factors are driving Hypertrophic Cardiomyopathy Market Trends @ Hypertrophic Cardiomyopathy Market Trends [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
1 Key Insights
2 Report Introduction
3 Hypertrophic Cardiomyopathy Market Overview at a Glance
4 Epidemiology And Market Forecast Methodology
5 Executive Summary of Hypertrophic Cardiomyopathy
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Products
12 Hypertrophic Cardiomyopathy: Market Analysis
13 KOL Views
14 SWOT Analysis
15 Unmet Needs
16 Reimbursement and Market Access
17 Appendix
18 Bibliography
19 Report Methodology
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertrophic-cardiomyopathy-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-medication-patient-pool-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight here
News-ID: 3862763 • Views: …
More Releases from ABNewswire
Tundrr Carbon-Based Soil Conditioner for Global Buyers: Specification-Led Sourci …
Tundrr Carbon-Based Soil Conditioner provides global buyers with a specification-led soil-improvement sourcing option from China. Formulated with greater than or equal to 35% organic matter, greater than or equal to 25% biochar, plus defined calcium, silicon, and magnesium content, it is designed for soil-structure and acidic-soil management programs. Tundrr supports quality control and export coordination for agricultural buyers.
As growers, agricultural distributors, private-label programs, and soil-management projects place greater emphasis on…
ROAM Roof & Solar Launches Radiant Barrier Service as Central Texas Homeowners S …
As ERCOT forecasts record power demand across Texas this summer, Belton-based ROAM Roof & Solar has launched a radiant barrier program backed by U.S. Department of Energy testing - aimed at helping homeowners reduce attic heat and ease the strain on rising electric bills.
BELTON, Texas - July 30, 2026 - ROAM Roof & Solar, a veteran-owned roofing, siding, gutters, solar, and waterproofing company, today announced the launch of its radiant…
Sunbird Carpet Cleaning of Columbia Says One Red Wine Spill Still Stands Out Aft …
The call came on a Tuesday morning from a homeowner in Columbia's Hickory Ridge neighborhood. Friends had gathered over the weekend, someone tipped over a glass of Cabernet, and red wine soaked into a light-colored living room carpet. The family reached for paper towels, club soda, and a grocery-store stain remover. Three days later, the stain had grown darker, the carpet felt stiff, and the spill had spread well beyond…
Baltimore Carpet & Upholstery Finds a Home Office Frozen in Time Beneath One Des …
The desk hadn't moved in nearly five years. When a Roland Park homeowner finally rolled it aside before a scheduled carpet cleaning, technicians from Baltimore Carpet & Upholstery uncovered something few people expect to see: a detailed record of thousands of workdays preserved in the carpet since 2020.
A software engineer living in Baltimore's Roland Park neighborhood scheduled a carpet cleaning after deciding to reclaim a spare bedroom that had served…
More Releases for Hypertrophic
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate?
In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its…
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate?
In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its…
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate?
The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines.
The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is…
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate?
The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines.
The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is…
Hypertrophic Cardiomyopathy Market - Empowering Lives, Elevating Heart Health: H …
Newark, New Castle, USA: The "Hypertrophic Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hypertrophic Cardiomyopathy Market: https://www.growthplusreports.com/report/hypertrophic-cardiomyopathy-market/8833
This latest report researches the industry structure, sales, revenue,…
Hypertrophic Scar Treatment market
The global Hypertrophic Scar Treatment market report published by Reports and Data assesses the Hypertrophic Scar Treatment market with regards to market size, market share, revenue growth, key segments, and regional bifurcation. The global Hypertrophic Scar Treatment market is highly fragmented with numerous players operating on a global and regional level. The companies are engaged in mergers and acquisitions, joint ventures, and collaborations along with product advancements and R&D activities…
